Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.

Published in: The Journal of clinical endocrinology and metabolism (2024)

In a diverse real-world setting, prescription of romosozumab for osteoporosis is associated with less adverse CV events when compared to PTH analog therapy.

Keyphrases

postmenopausal women
bone mineral density
molecular docking
emergency department
stem cells
combination therapy
smoking cessation
adverse drug
drug induced